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Abstract
Background: The challenges in diagnosis of rare renal conditions can negatively impact patient prognosis, quality
of life and result in significant healthcare costs. Differential methylation is emerging as an important biomarker for
rare diseases and should be evaluated for rare renal conditions.
Methods: A comprehensive systematic review of methylation and rare renal disorders was conducted by searching
the electronic databases MEDLINE, EMBASE, PubMed, Cochrane Library, alongside grey literature from GreyLit and
OpenGrey databases, for publications published before September 2018. Additionally, the reference lists of the
included papers were searched. Data was extracted and appraised including the primary focus, measurement and
methodological rigour of the source. Eligibility criteria were adapted using the inclusion criteria from ‘The 100,000
Genomes Project’ and The National Registry of Rare Kidney Diseases, with additional focus on methylation.
Results: Thirteen full text articles were included in the review. Diseases analysed for differential methylation
included glomerular disease, IgA nephropathy, ADPKD, rare causes of proteinuria, congenital renal agenesis, and
membranous nephropathy.
Conclusions: Differential methylation has been observed for several rare renal diseases, highlighting its potential
for improving molecular characterisation of these disorders. Further investigation of methylation following a
standardised reporting structure is necessary to improve research quality. Multi-omic data will provide insights for
improved diagnosis, prognosis and support for individuals living and working with rare renal diseases.
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Background
Whilst rare diseases are uncommon at the individual level,
cumulatively they represent a significant public health
problem with approximately 350 million people suffering
worldwide [1]. The definition of a rare disease varies be-
tween continents; the European Commission classifies a
rare disease as one which affects less than five people in
10,000, whilst the American definition states rare diseases
affect fewer than 200,000 people [1]. An underlying gen-
etic cause is suspected in 80% of rare conditions, with 50%
of these diseases occurring in children. Two in five pa-
tients with rare diseases describe struggling to obtain a
timely accurate diagnosis which can be detrimental to
each individual’s quality and length of life [2]. Interpret-
ation of massive amounts of genetic information gener-
ated by large scale sequencing efforts remains a challenge;
but despite this, these efforts are significantly improving
the speed and accuracy of rare disease diagnosis [3]. Add-
itionally, rationalising data generated by multi-omic ap-
proaches could provide new insights into molecular
profiles for rare diseases.
More than 100 rare renal disorders have been reported
[4, 5]. Similar to many other rare diseases, clinical diagnosis
of rare renal diseases may be challenging with limited clin-
ically relevant biomarkers, significant phenotypic variability,
poor understanding of the disease pathogenesis and a lack
of appropriate therapies. For example, diagnosis of IgA ne-
phropathy (IgAN) involves a renal biopsy to confirm
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diagnosis which is an invasive and relatively expensive
procedure [6]; diagnosis of polycystic kidney disease
(PKD) utilises ultrasound scanning for diagnosis, which is
insufficiently sensitive to detect the earliest stages of PKD
even though earlier detection may improve the patient’s
prognosis [7]. The development of a panel of cost-effi-
cient, sensitive and accurate biomarkers of rare kidney dis-
ease which can be detected non-invasively would greatly
aid rare renal disease diagnosis. A biomarker is defined as
“a characteristic that is objectively measured and evaluated
as an indicator of normal biological processes, pathogenic
processes, or pharmacologic responses to a therapeutic
intervention” [8]. At present, biomarkers to identify renal
dysfunction are sub-optimal and often based on inexact
biochemical markers where half of ‘normal’ kidney func-
tion is lost before kidney disease is identified. Additionally
it is important to note that kidney dysfunction (associated
with gene variants or complex chromosome abnormal-
ities) can have widespread impacts on other organ systems
[5]. Therefore, multi-centre studies are required to estab-
lish disease-based cohorts for rare renal disease with con-
sistent biological sample collection, harmonised
biomarker measurements, effective data sharing, and com-
patible analytics across all data.
Unravelling the genetic basis of rare kidney disorders has
been facilitated by the establishment of rare renal disease
biobanks and registries such as The PodoNet Registry for
congenital and steroid resistant nephrotic syndrome [9], the
UK National Registry of Rare Kidney Diseases (RaDaR) [10],
and the development of focused international professional
multidisciplinary teams such as the ERA-EDTA Working
Group on Inherited Kidney Disorders [11]. Current research
to improve knowledge of disease is moving beyond simple
changes to the DNA sequence to utilising integrated multi-
omic strategies to improve clinical diagnosis [12]. There are
517 omics currently described [13], with transcriptomics
(RNA-based), epigenomics (DNA and RNA based non se-
quence level modifications), and proteomics being the pri-
mary research tools for rare renal diseases at present.
Integrated molecular and clinical approaches are increasingly
being employed to provide functional evidence for pathogen-
icity of SNPs (single nucleotide polymorphisms) and to de-
liver novel disease insights [14–17].
Methylation, the addition of a chemical methyl group
via DNA methyl transferases, is a key epigenomic feature
affecting gene expression. Methylation predominately oc-
curs in CpG dinucleotides (though it can occur elsewhere)
where the methyl group is added to the fifth carbon of the
cytosine forming 5-methylcytosine (5mc) [18]. Large-scale
methylome-wide studies have allowed better understand-
ing of DNA methylation and health-related outcomes, for
example using Illumina’s Infinium MethylationEPIC array,
which quantitatively and cost effectively interrogates ap-
proximately 850,000 features [19], or deep whole-genome
bisulfite sequencing of genomic DNA [20]. Evidence is
growing that methylation risk scores (analogous to genetic
risk scores) may be constructed for multiple health out-
comes [21]. Methylation is largely considered be a tran-
scriptional repressor with roles in genomic imprinting [22],
X Chromosome inactivation [23], repression of repetitive
elements [24], aging [25] and tissue specific gene expression
[26]. The location of the methylated sites affects function,
for example methylation within the gene body rather than
the classically thought of transcriptional start sites may have
a role in transcriptional activation [27].
Aberrant methylation is implicated in multiple disor-
ders affecting a range of organ systems. These include,
but are not limited to, vascular complications in type 2
diabetes despite good glycaemic control [28], several
cancers [29], clinical heterogeneity in Alzheimer’s dis-
ease [30], pre-natal and early childhood neurodevelop-
mental disease [31], development of chronic kidney
disease [32, 33], and differential methylation has even
been implicated by a number of studies as potentially
impacting kidney transplant outcomes through alloim-
mune response and ischemia–reperfusion injury [34].
The crucial role of DNA methylation in monoallelic im-
printing is now evident from disorders of methylation,
when aberrant methylation has detrimental effects on
development, as is often the case in Prader–Willi syn-
drome, Silver–Russell syndrome, Beckwith–Wiedemann
syndrome and Type Ib pseudohypoparathyroidism [35,
36]. The sophistication of epigenetic tools for disease
characterisation continues to improve, such as the devel-
opment of the EpiSign assay which can aid the diagnosis
of 19 often difficult to identify disorders, including
Angelman Syndrome, Prader-Willi syndrome and Beck-
with-Wiedemann syndrome [37]. DNA methylation can
be influenced by inherited (genetic) and acquired
throughout life (somatic; environmental) factors, cre-
ating changes that may be short-acting, exist long-
term in an individual, and / or demonstrate transge-
nerational inheritance. Several recent multi-centre pa-
pers confirm socioeconomic experiences across the
life course impact peripheral blood-derived methyla-
tion, persisting from pre-birth, throughout childhood,
to later adult life [38–41].
Aims and objectives
This review summarises current evidence that exists for
differential methylation in rare renal diseases by:
1. Identifying rare renal diseases that have been
analysed for differential methylation.
2. Determining how differential methylation has been
measured and in which genomic regions.
3. Discussing the potential for differential methylation
as a diagnostic biomarker for rare renal diseases.
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Methods
This review was designed using the Preferred
Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) systematic review checklist
(Additional file 1) [42].
Eligibility criteria
Quantitative articles written in English and published
before September 2018 were included if they were rele-
vant to non-cancerous rare renal diseases which appear
in the inclusion criteria from ‘The 100,000 Genomes
Project’, [43] and were directly relevant to aberrant
DNA methylation. Studies of kidney cancer and differen-
tial methylation was excluded as this has been previously
reviewed [44]. Further articles were included if they were
relevant to a condition that appeared on the inclusion
criteria of the Registry of Rare Renal Diseases (RaDaR).
It should be noted that although Autosomal Dominant
Polycystic Kidney Disease (ADPKD) is not classed as a
rare disease, the acquisition of a second mutation that
causes the disease (a two-hit hypothesis) is a rare
phenomenon and so it meets ‘The 100,000 Genomes
Project’ inclusion criteria and that of this review. How-
ever, any rare renal disease included in RaDaR that was
explicitly excluded in ‘The 100,000 Genomes Project’
was not included in search terms (e.g. Shiga toxin associ-
ated atypical-HUS). Of the RaDaR inclusion criteria, rare
diseases that have renal involvement, but which are not
primarily classed as a renal disease were also excluded.
These were; vasculitis, tuberous sclerosis, retroperitoneal
fibrosis, pure red cell aplasia, hyperoxaluria, HNF-1B
mutations, fibromuscular dysplasia, Fabry disease, EAST
syndrome and calciphylaxis.
Information sources and search terms
Four electronic databases were searched for identifica-
tion of primary sources: MEDLINE via Ovid, EMBASE
via Ovid, PubMed and Cochrane Library. It is worth
noting that PubMed was searched in addition to MED-
LINE, as MEDLINE is a subset of PubMed which allows
more specific searching but can return different results
[45]. A search was also conducted of grey literature
using the databases GreyLit and OpenGrey. Reference
lists of included papers were also screened for further
sources. Finally, websites genomeweb (https://www.gen-
omeweb.com/) and Epigenesys (https://www.epigenesys.
eu/en/) were searched for relevant articles. Search terms
were created using the Population, Intervention, Com-
parison, Outcome (PICO) framework [46], primarily for
use in MEDLINE and adapted for search in other data-
bases, (see Additional file 2: Table S1). That is, the
population of interest were patients or models of the
rare renal diseases, interventions were varying measure-
ments of differential methylation, comparisons were the
individuals/samples without these rare renal diseases,
and the possible outcomes were identification of differ-
ential methylation elucidating any potential applications
to improve patient health or quality of life.
Study selection, data extraction and critical appraisal
Database searches were last conducted on the 17th Sep-
tember 2018. Duplicates were removed, and the remaining
papers were screened through analysis of their titles, ab-
stracts and keywords for relevance. If relevant, the papers
were then further screened by reading the full text. Refer-
ences and forward citations were also screened of the
remaining papers to look for any further relevant papers.
Data was extracted, (in duplicate by two independent
personnel) and sources were critically appraised using a
customised form modelled on the Joanna Briggs Institute
Critical Appraisal tools [47], templates of which are avail-
able in (Additional file 2: Tables S2 and S3). Methodo-
logical rigour was scored as being weak, moderate, or
strong with decisions based on choice of appropriate con-
trols, how study limitations were addressed and the use of
appropriate statistical analysis.
Results
Sources initially identified from each database were as
follows, MEDLINE n = 58, EMBASE n = 136, PubMed
n = 62, Cochrane Library n = 1, GreyLit n = 0, OpenGrey
n = 0. Following title and abstract screening, 94 dupli-
cates were removed and 15 papers were identified for
full text screening. No further studies were identified
from searching genomeweb and Epigenesys publication
databases. Finally, 13 texts were included in the full re-
view, (Fig. 1), with the characteristics of each source
summarised from the completed data extraction forms,
(Additional file 2: Table S4). This included study aims,
design information, methylation measurement, meth-
odological rigour and key results. Outcomes, methyla-
tion measurement and participant information are
briefly summarised (Table 1). Of the texts included, 12
were case-control studies and one was a case report. Ref-
erence lists of these papers and forward citations were
also screened but no further sources were identified.
Of the 13 articles included in this review, three origi-
nated from South Korea, two from China, one from
Italy, one from Canada, three from the United States
of America and three from Japan. Methodological
rigour was assessed as weak for all studies, primarily
based on lack of description dealing with limitations,
such as regression to identify confounding factors,
lack of appropriate matching of cases to controls on
the basis of gender, age or ethnicity, and often a lack
of detail on experimental controls, statistical analysis
or animal model strains used.
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Discussion
After systematically evaluating current publications relevant
to differential methylation in patients with rare renal dis-
eases, this review has identified limited evidence for differen-
tial methylation in rare renal diseases. However, what
evidence exists is promising and highlights the need for fur-
ther research to explore differential methylation as a diagnos-
tic and / or prognostic biomarker of rare renal diseases.
DNA methylation and renal cancer is reviewed extensively
elsewhere and is not discussed in this review [44].
At present, although rare forms of kidney disease signifi-
cantly affect individuals living with these conditions, there
is very poor understanding of the molecular characteristics
and best treatment options for these conditions. Even
where the underlying genetic cause is known for a rare
renal disease there may still be significant unexplained
heterogeneity in phenotypes between individuals with the
same genotype. Therefore, studying epigenetic features,
such as DNA methylation, may offer new insights by pro-
viding a mechanism to understand how each individual’s
genome interacts with their environment through the epi-
genome. However, this review highlights that only a small
number of studies have been reported researching differ-
ential methylation in rare renal diseases:
 IgAN [48–50]
 ADPKD [51–53]
 Rare diseases causing proteinuria including
membranous nephropathy [54, 55] and focal
segmental glomerulosclerosis (FSGS) [56–59]
 Congenital renal agenesis [60]
This reflects only 5% of the approximated total num-
ber of rare renal diseases which exist and thus a signifi-
cant gap in published research has been identified [4, 5].
IgAN is a condition wherein Immunoglobulin A accu-
mulates in kidney tissues and results in harmful inflam-
mation, which can ultimately lead to end stage renal
disease (ESRD) requiring dialysis and renal replacement
therapy (RRT). IgAN was a disease included in the
RaDaR recruitment criteria and familial IgAN was in-
cluded in the 100,000 Genomes Project eligibility cri-
teria. In the three studies of IgAN included in this
review, DNA methylation was measured through chro-
matin immunoprecipitation (ChIP) microarray, whole
genome microarray analysis of bisulphite converted
DNA and methylation specific polymerase chain reaction
(MSP). Aberrant methylation was identified as a poten-
tial driver in IgAN pathogenesis when identified in
CD4+ T cells by causing T helper cell imbalances [49],
as a contributor to abnormal glycosylation of IgA1 in
IgAN through differential methylation of Cosmc [48],
and as alterations in the H3K4me3 status identified in
IgAN patients along with three significantly differentially
methylated candidate genes (FCRL4, IL1RAPL1 and
PTPRN2) that may exacerbate IgAN pathology through
mediating the cytokine/chemokine cascade and inhib-
ition of protein tyrosine kinase respectively [50].
ADPKD, included in the 100,000 Genomes Project
and RaDaR eligibility criteria, is a disease where patients
suffer from the growth of cyst formation on the kidney
can lead to ESRD and other complications such as kid-
ney stones, polycystic liver disease and brain aneurysms.
Fig. 1 Illustration of search strategy including databases searched and screening methods modelled on the PRISMA flow diagram
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Table 1 Overview of study characteristics, ordered alphabetically by rare renal disease type
First author,
year and rare
kidney disease
featured.
Methylation measurement method Participant information. Outcome
Fujino,
Takayuki. 2016
Disease:
Membranous
Nephropathy
ChIPa assays and H3K4me3b
localisation.
Renal biopsies from patients (n = 6)
diagnosed with nephrotic syndrome caused
by membranous nephropathy compared to
controls with other causes of nephrotic
syndrome. Two additional control
comparisons were participants with
microhematuria but no
glomerulonephropathy (n = 3) and a single
age matched healthy control. Also murine
models with induced proteinuria.
The association of increased H3K4me3 and
cathepsin L as well as decreased
synaptopodin levels and proteinuria in
membranous nephropathy.
Hayashi, K.
2014
Disease:
Proteinuria
Micro-array based genome wide
DNAcmethylation profiling system,
MSPd and bisulphite sequencing.
Murine models of proteinuric disease,
including FSGSe (n = 11), minimal change
disease (n = 10), diabetic nephropathy (n = 9)
and normal controls (n = 9). Human renal
biopsies from the same proteinuric diseases,
number not stated.
Elucidation of a potential novel therapeutic
target of proteinuria, the gene KLF4,
including investigation of promoter CpG
methylation.
Hayashi, K.
2015
Disease:
Proteinuria
Bisulphite treatment of DNA and MSP. Murine models of adriamycin nephropathy,
(n = 5 in each treatment group). Samples
from patients with proteinuric glomerular
diseases including FSGS (n = 8), minimal
change disease (n = 9), diabetic nephropathy
(n = 8) and normal controls (n = 8). Immortal
human podocyte cell lines.
Identification of KLF4 as a potential
therapeutic target of proteinuria and
angiotensin receptor blockers as a treatment
which exerts effects on methylation.
Ito, Y. 2017
Disease:
Proteinuria
ChIP assays of histone methylation. Human embryonic kidney cell lines as well
as murine and zebrafish models of
proteinuria.
The role of WHSC1L1-L1 in epigenetically
modifying the expression of nephrin, with
implications for both congenital nephrotic
syndrome (rare) and acquired nephrotic
syndrome (non-rare).
Jin, M. 2014
Disease:
Congenital
renal agenesis
Reduced representation bisulphite
sequencing to allow analysis of
differentially methylated regions.
Chinese female monozygotic twins
discordant for congenital renal agenesis.
Genomic/epigenomic changes, including
methylation, which may be correlated with
congenital renal agenesis in discordant
monozygotic twins.
Li, LX. 2017
Disease:
ADPKDf
ChIP with anti-H3K4me2g antibodies
and anti-SMYD2 antibodies.
Methylation sites localised using a flag-
tagged protein.
Double conditional knockout of Pkd1 and
Smyd2 in murine models of ADPKD (n = 12)
compared to single knockout of Pkd1 (n =
14). Treatment of mice (n = 12) of ADPKD
(Pkd1 knockouts) with AZ505 compared to
DMSOh injected controls (n = 12) and in
conditional Pkd1 knockouts (n = 14)
compared again to DMSO injected controls
(n = 14). Human ADPKD cells were also
utilised and compared to normal kidney
cells.
SMYD2’s potential role in ADKPD cyst
formation, including differential methylation.
Majumder,
Syamantak.
2018.
Disease:
Proteinuria
Immunohistochemical staining, RT-
qPCRi and ChIP assays of H3K27me3j.
Murine models with induced glomerular
injury compared to controls. Kidney samples
of human participants with diabetic
glomerulosclerosis (n = 12) compared to age
matched healthy controls (n = 12) and FSGS
(n = 10) compared to non-FSGS tissue
biopsies taken at the time of kidney
transplantation (n = 9).
Reduced H3K27me3 and subsequent
upregulation of the Notch pathway as a
contributor to albuminuria in glomerular
disease.
Qi, S. 2012
Disease: IgANk
ChIP microarray and real time
quantitative MSP.
PBMCsl from IgAN patients (n = 15) and
healthy controls (n = 15).
Identification of H3K4me3 as a potential
contributor to IgAN.
Sallustio, F.
2016
Disease: IgAN
Whole genome microarray analysis of
CD4+ T cells, followed by
pyrosequencing for validation.
Renal biopsies from IgAN patients (n = 24)
and normal controls (n = 24).
Differential methylation in CD4+ T-cells as a
potential contributor to IgAN pathogenesis.
Sui, WG. 2014
Disease:
Membranous
nephropathy
ChIP-sequencing of H3K9me3m
followed by Model-based Analysis of
ChIP-sequencing which identified
enriched H3K9me3 peaks.
PBMCs from membranous nephropathy
patients (n = 10) and healthy controls (n =
10).
Identification of H3K9me3 alterations,
including differential methylation, as a
potential contributor to membranous
nephropathy pathogenesis and a potential
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Our systematic review identified three studies of DNA
methylation and ADPKD, where methylation was mea-
sured through ChIP and methylated-CpG island recov-
ery assays (MIRA-Seq). These studies identified
differential methylation to have a role in ADPKD via up-
regulation of SMYD2 contributing to renal cyst formation
due to methylation of STAT3 and p65, subsequently
resulting in increased renal cell proliferation [53], epigen-
etic silencing of PKD1 and other ion transport genes in
ADPKD due to hypermethylation [52], and identification
of reduced expression of MUPCDH as a prognostic bio-
marker of ADPKD [51]. Of interest, the latter two of three
studies noted that treatment with methylation inhibitor al-
leviated cyst formation, thus identifying novel therapeutic
targets for ADPKD.
Six of the included articles discussed rare causes of pro-
teinuria, including membranous nephropathy and FSGS
(FSGS is included in the RaDaR recruitment criteria). Mem-
branous nephropathy is a rare auto-immune glomerular dis-
ease with a global average incidence of 2.5/100,000
individuals [61], characterised by thickening of the glomeru-
lar wall and decreased filtration, leading to proteinuria and
ultimately loss of kidney function. Our review identified two
articles of differential methylation in membranous nephropa-
thy, measured by ChIP sequencing and assays. Increased
H3K4me3 was found to exacerbate proteinuria in membran-
ous nephropathy [55], with murine models showing that tar-
geting shRNA against an H3K4 methyltransferase, MLL3,
alleviated proteinuria. H3K9me3 alterations were also found
to be a biomarker of membranous nephropathy compared
to normal control patients [54]. FSGS, included in the
RaDaR elgibility criteria, is a condition describing sclerosis of
the kidney, with a variety of causes. Three studies of
proteinuria featuring FSGS and differential methylation were
included, measured by whole genome microarray, MSP and
ChIP assays. These studies identified that aberrant methyla-
tion in FSGS may cause proteinuria by downregulation of
KLF4, which has a role in reprogramming somatic cells into
induced pluripotent stem (iPS) cells [57]. This was further in-
vestigated to show that downregulation of KLF4 causes
nephrin promoter methylation leading to development of
proteinuria, which can be alleviated by treatment with an
angiotensin receptor blocker (ARB), thus identifying a poten-
tial therapeutic target [56]. Interestingly, nephrin was also
found to regulate epigenetically in proteinuria caused by
FSGS, through aberrant methylation of WHSC1L1-L
through interaction with H3K4 and H3K36 [58]. Downregu-
lation of H3K27me3 causing subsequent upregulation of the
Notch pathway was found to be associated with albuminuria
in glomerular disease, including FSGS [59].
Finally, our comprehensive search identified one study
of differential methylation in congenital renal agenesis
[60]. Congenital renal agenesis is defined as a condition
where one or both kidneys are missing at birth. In this
case report of discordant monozygotic twins with con-
genital renal agenesis, differentially methylated regions
are identified but location and whether this is an in-
crease/decrease in methylation is not specified, as well as
no discussion of the potential function of these differen-
tially methylated regions.
A number of the studies included in this review inves-
tigated methylation in animal models and cell lines,
which are imperfect models of human kidney disease
[53, 58]. Therefore, it would be helpful to also analyse
these candidate differentially methylated genes using
DNA isolated from kidney biopsy tissue, saliva, urine or
Table 1 Overview of study characteristics, ordered alphabetically by rare renal disease type (Continued)
First author,
year and rare
kidney disease
featured.
Methylation measurement method Participant information. Outcome
biomarker.
Sun, Q. 2015
Disease: IgAN
MSP of bisulphite treated Cosmc gene
promoter regions.
PBMCs from paediatric patients with IgAN
(n = 26), other renal diseases (n = 11) and
healthy control children (n = 13).
Differential methylation in the Cosmc gene
as a potential contributor to aberrantly
glycosylated IgA1 in IgAN patients.
Woo, YM. 2014
Disease:
ADPKD
MIRA-seqn and ChIP-qPCR. Cystic renal cortex samples from ADPKD
patients (n = 3) and non-ADPKD samples
from renal cell carcinoma patients (n = 3)
used as a normal control. Madin-Darby
Canine Kidney cells also used.
Differential methylation in ADPKD cyst
formation and the role of methylation
inhibitors in repression of cyst formation.
Woo, YM. 2015
Disease:
ADPKD
MIRA-seq, methylation-sensitive high-
resolution melting and validation using
EpiTYPER assay.
Renal tissue from ADPKD patients (n = 3) and
non-ADPKD healthy renal tissue from renal
cell carcinoma patients (n = 3). Urine
samples of ADPKD patients evaluated over a
period of 21 months (n = 53).
Identification of differentially methylated
MUPCDH as a potential prognostic
biomarker of ADPKD.
Abbreviations. aChIP chromatin immunoprecipitation, bH3K4me3 histone three lysine three trimethylation, cDNA Deoxyribonucleic acid, dMSP methylation specific
polymerase chain reaction, eFSGS focal segmental glomerulosclerosis. fADPKD autosomal dominant polycystic kidney disease, ganti-H3K4me2 anti-histone 3 lysine 4
dimethylated, hDMSO dimethyl sulfoxide, iRT-qPCR quantitative reverse transcription polymerase chain reaction, jH3K27me3 histone three lysine 27 trimethylation,
kIgAN IgA nephropathy, lPBMCs peripheral blood mononuclear cells, mH3K9me3 histone three lysine 9 trimethylation, nMIRA-seq methylated-CpG island
recovery assay
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blood in patients with rare renal diseases to assess their
utility as diagnostic biomarkers from a minimally inva-
sive test that could be routinely performed in clinic or at
a GP surgery; this would minimise risk to patients and
improve cost-effectiveness for healthcare professionals.
Despite the scope of this review including literature from
1946, the research identified and described in this review has
been conducted within the last decade, reflecting growing
awareness of the potential utility of epigenetics in renal dis-
ease. Whilst this is encouraging, the studies measured differ-
ential methylation in fundamentally different ways and as
such comparison between the outcomes were difficult. These
different approaches to research methylation were as follows:
 Variations in histone tri-methylation status [50, 54,
55, 58, 59]
 Methyl-transferase activity and impact on signalling
pathways [53]
 Hyper/hypo methylation of promotor regions [48,
49, 51, 56–58], and gene bodies [49, 52]
The final objective of this review was to evaluate any re-
search which highlighted the potential for differential methy-
lation as a diagnostic biomarker of rare renal disease. Only
two of the studies discussed this potential biomarker devel-
opment, one being the potential of methylation as a diagnos-
tic biomarker for membranous nephropathy [54] and one
the potential for a prognostic biomarker of ADPKD [51].
The focus of the majority of the articles was elucidating
pathogenic mechanisms or developing a novel therapies.
Therefore, this review highlights that although limited evi-
dence does exist for differential methylation influencing rare
renal diseases, further research is required to robustly iden-
tify differentially methylated features which could be poten-
tial biomarkers and to perform validation studies on such
features.
The scarce nature of rare diseases makes it difficult to
perform “gold standard” experimental design studies,
such as an ethical randomised control trial with strong
methodological rigour. One consistent limitation seen
across studies included in this review was a lack of ac-
counting for confounding factors in all case-control
studies, even though such factors were frequently identi-
fied in the discussion and regression analysis may have
been appropriate to improve the methodological rigour.
This is typical for a developing field, therefore future
studies would benefit from standardisation of the detec-
tion and analysis of methylation, the inclusion of more
robust (laboratory and computational) quality controls,
and a comprehensive, transparent reporting structure
such as exists for genetic association studies [62].
The wide range of countries from which this research
has originated is encouraging since international collab-
oration is essential to maximise the power of any study
given the scarcity of participants with rare renal diseases.
Projects such as UK’s 100,000 Genomes Project have left a
lasting legacy with ongoing multi-omic analysis (including
DNA methylation) currently helping extend understand-
ing and knowledge of rare renal conditions [43]. Add-
itional research would also be helpful to explore if there
are significant differences associated with methylation and
rare renal diseases between different ethnic groups.
Conclusions
This review highlights that there has been limited investiga-
tion of differential methylation for rare renal diseases, but
this limited research is encouraging and will help guide fu-
ture studies. For example, differential methylation of mem-
branous nephropathy cases compared to healthy controls,
significant hypermethylation and under expression of
mucin-like protocadherin (MUPCDH) between ADPKD
kidney tissue and non-ADPKD kidney tissue, differentially
methylated regions in congenital renal agenesis, and signifi-
cantly higher DNA methylation in genes FCRL4, PTPRN2
and IL1RAPL1 of IgAN patients compared to healthy con-
trols; all of which highlight DNA methylation as a potential
novel biomarker of rare renal disease. Further research
focus is required for standardised, international multi-omic
analysis of rare renal diseases towards developing a panel of
biomarkers with clinical utility. Development of differential
methylation diagnostic biomarkers could offer significant
aid to patients requiring diagnosis and the health-care pro-
fessionals struggling to provide diagnosis.
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